Sofinnova and 5AM lead £28m series-A for NodThera

Epidarex Capital and F-Prime Capital Partners also took part in the round, which will enable the company to develop its leading drug candidate for the clinical trial stage.

Sofinnova managing partner Henrijette Richter and 5AM founding partner Scott Rocklage will take a seat on the NodThera board of directors, with the former taking on the role of chairperson.

Company
Founded in 2016, Cambridge-headquartered NodThera is a drug discovery company focusing on the development of inflammasome inhibitors for the treatment of diseases driven by chronic inflammation.

People
Sofinnova Partners – Henrijette Richter (managing partner).
5AM Ventures – Scott Rocklage (founding partner).
Epidarex Capital – Elizabeth Rope (partner).
NodThera – Alan Watt (chief scientific officer, acting CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• Venture
• Sofinnova Partners